Irinotecan Kabi

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Kabi, is a topoisomerase I inhibitor presented as an injectable solution for intravenous use. It is employed in the treatment of metastatic colorectal cancer in adult patients.

GNH USA supplies Irinotecan Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides cold‑chain logistics where required, ensuring product integrity from manufacturing to end‑user. Customers receive regulatory documentation and support for import clearance.

Irinotecan Kabi is a topoisomerase I inhibitor employed in oncology regimens targeting gastrointestinal and thoracic malignancies. - Metastatic colorectal cancer: used in combination regimens to inhibit tumor growth and extend survival. - Small cell lung cancer: incorporated into multi‑drug chemotherapy to achieve tumor response and disease control. - Advanced gastric cancer: employed as part of multi‑agent protocols to manage disease progression. - Pancreatic cancer: used off‑label within combination therapy to attempt tumor reduction. - Ovarian cancer: occasionally combined with other agents in experimental protocols for disease management.

Irinotecan Kabi may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Diarrhea - Nausea - Neutropenia - Fatigue

Serious or Rare Side Effects: - Severe neutropenia with fever - Life‑threatening colitis - Hypersensitivity reactions (anaphylaxis)

When using Irinotecan Kabi, clinicians should observe several precautionary measures to minimise risk. - Monitor blood counts: perform regular complete blood count assessments to detect neutropenia early. - Assess liver function: evaluate hepatic enzymes before and during therapy as impairment can increase exposure. - Evaluate gastrointestinal status: avoid use in patients with recent bowel obstruction or severe diarrhea. - Adjust for hypersensitivity: discontinue immediately if signs of an allergic reaction appear. - Dose modification in hepatic impairment: reduce dose according to liver function test results. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan Kabi can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): markedly reduce irinotecan plasma levels. - Concurrent myelosuppressive agents: increase risk of severe neutropenia and thrombocytopenia.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may raise irinotecan exposure. - Anticoagulants such as warfarin: potential alteration of INR, requiring monitoring. - Drugs affecting biliary excretion (e.g., probenecid): could modify SN‑38 clearance.